secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001062822-25-000019
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon licenses LX9851 to Novo Nordisk for $45M upfront; amends Oxford loan with $45M prepayment
--------------------------------------------------------------------------------

- Exclusive worldwide license to Novo Nordisk for LX9851 (obesity/cardiometabolic); Lexicon receives $45M upfront, eligible for up to $485M regulatory/commercial milestones and $475M sales milestones.
- Lexicon entitled to tiered single- to low-double-digit royalties on annual net sales; Novo Nordisk responsible for development and commercialization.
- Lexicon amended its Oxford loan, using $45M upfront to prepay $42.06M principal plus $2.94M final payment; prepayment fee waived.
- Loan amendment modifies amortization date to May 1, 2027 (or Dec 1, 2026 if certain event fails) and replaces net sales covenant with minimum cash covenant of $29M or 50% of outstanding principal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282225000019/0001062822-25-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282225000019/lxrx-20250327.htm
  HTML page:      https://secwatch.observer/filing/0001062822-25-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer